SHUBHADA V MANGRULKAR

Dr. SHUBHADA V MANGRULKAR

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Biophysical Reviews
Verified
Journal Article
Closed access
PDF file
TBTrupti A. Banarase
Trupti A. Banarase
SSShivkumar S. Sammeta
Shivkumar S. Sammeta
NWNitu L. Wankhede
Nitu L. Wankhede
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
SRSandip R. Rahangdale
Sandip R. Rahangdale
MKMayur Bhimrao Kale
Mayur Bhimrao Kale

6 January 2021 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
PSPranav Shah
Pranav Shah
SNSonali Navnage
Sonali Navnage
PMPriyanka Mazumdar
Priyanka Mazumdar
DCDinesh Chaple
Dinesh Chaple

9 March 2023 in Current Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
PPPriyanka Prajapati
Priyanka Prajapati
Anand KumarAnand Kumar
Anand Kumar
RCRishabh Chaudhary
Rishabh Chaudhary
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
MAMalti Arya
Malti Arya
SKSapana Kushwaha
Sapana Kushwaha
Background: As people age, physical impairments may have a deleterious role in skeletal muscles. Sarcopenia Clinical Practice Guidelines 2017 and the European Working Group on Sarcopenia in older people are two organizations that have published essential guidelines on the definition of “sarcopenia". Sarcopenia is a geriatric syndrome, characterized by skeletal muscle mass degeneration brought on by ageing, which lowers muscular function and quality. Moreover, sarcopenia can be classified as primary or age-associated sarcopenia and secondary sarcopenia. Also, secondary sarcopenia occurs when other diseases such as diabetes, obesity, cancer, cirrhosis, myocardial failure, chronic obstructive pulmonary disease, and inflammatory bowel disease also contribute to muscle loss. Furthermore, sarcopenia is linked with a high risk of negative outcomes, considering a gradual reduction in physical mobility, poor balance, and increased fracture risks which ultimately leads to poor quality of life. Objective: In this comprehensive review, we have elaborated on the pathophysiology, and various signaling pathways linked with sarcopenia. Also, discussed are the preclinical models and current interventional therapeutics to treat muscle wasting in older patients. Conclusion: In a nutshell, a comprehensive description of the pathophysiology, mechanisms, animal models, and interventions of sarcopenia. We also shed light on pharmacotherapeutics present in clinical trials which are being developed as potential therapeutic options for wasting diseases. Thus, this review could fill in the knowledge gaps regarding sarcopenia-related muscle loss and muscle quality for both researchers and clinicians.

29 July 2024 in Journal of Drug Targeting
Verified
Journal Article
Closed access
VPVrushali N. Patel
Vrushali N. Patel
HPHeta V. Patel
Heta V. Patel
KAKashish Agrawal
Kashish Agrawal
ISIshika Soni
Ishika Soni
PSPranav Shah
Pranav Shah
MLManisha S Lalan
Manisha S Lalan
The use of topical antimicrobials in wound healing presents challenges like risk of drug resistance and toxicity to local tissue. Simvastatin (SIM), a lipid-lowering agent which reduces risk of cardiovascular events, is repurposed for its pleiotropic effect in wound healing. A bioactive bioadhesive polymer-based film forming spray (FFS) formulation of SIM was designed using chitosan, collagen, hyaluronic acid and optimized by employing DoE approach. Optimized formulation demonstrated moderate viscosity (12.5 ± 0.3 cP), rapid film formation (231 ± 5.6 s), flexibility, tensile strength and sustained drug release (T80 - time for 80% drug release - 9.05 ± 0.7 h). Scanning electron microscopy (SEM) verified uniformly dispersed drug within composite polymer matrix. SIM FFS demonstrated antimicrobial activity against gram positive and gram negative bacteria. In vivo excision wound model studies in mice affirmed the beneficent role of bioactive polymers and the efficacy of SIM FFS in wound contraction and closure, tissue remodelling and re-epithelization in comparison to standard antimicrobial preparation. Cytokines TNF- alpha, IL-6 were downregulated and IL-10 was upregulated. Biochemical markers; hydroxyproline, hexosamine and histopathology were consistent with wound contraction observed. This is an exploratory effort in repurposing SIM for wound healing in a novel dosage form, underscoring its potential as an alternative to conventional topical antimicrobials.

11 October 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MKMonu Kumar Kashyap
Monu Kumar Kashyap
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
SKSapana Kushwaha
Sapana Kushwaha
AVAKASH VED
AKASH VED
MKMayur Bhimrao Kale
Mayur Bhimrao Kale
SKSpandana Rajendra Kopalli
Spandana Rajendra Kopalli
Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy regimen for colorectal, gastric, and breast cancers, cardiotoxicity caused by 5-fluorouracil might affect anywhere from 1.5% to 18% of patients. The precise mechanisms underlying cardiotoxicity associated with CRC treatment are complex and may involve the modulation of various signaling pathways crucial for maintaining cardiac health including TKI ErbB2 or NRG-1, VEGF, PDGF, BRAF/Ras/Raf/MEK/ERK, and the PI3/ERK/AMPK/mTOR pathway, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, ultimately damaging cardiac tissue. Thus, the identification and management of cardiotoxicity associated with CRC drug therapy while minimizing the negative impact have become increasingly important. The purpose of this review is to catalog the potential cardiotoxicities caused by anticancer drugs and targeted therapy used to treat colorectal cancer as well as strategies focused on early diagnosing, prevention, and treatment of cardiotoxicity associated with anticancer drugs used in CRC therapy.

13 July 2024 in Advances in Traditional Medicine
Verified
Journal Article
Closed access
PDF file
SMSHUBHADA V MANGRULKAR
SHUBHADA V MANGRULKAR
SKSayli S. Kulkarni
Sayli S. Kulkarni
PNPratiksha V. Nanepag
Pratiksha V. Nanepag
PNPankaj S. Neje
Pankaj S. Neje
DCD. R. Chaple
D. R. Chaple
MUMilind Janrao Umekar
Milind Janrao Umekar